Lv5
963 积分 2022-10-08 加入
Path Less Traveled: Targeting Rare Driver Oncogenes in Non–Small-Cell Lung Cancer
12小时前
已完结
A Comprehensive Analysis of HER2 status Heterogeneity Using Matched Samples Among Potential Beneficiaries of Trastuzumab Deruxtecan Therapy In Non-Small Cell Lung Cancer
12小时前
已完结
Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2025.1
12小时前
求助中
Zongertinib in Previously Treated HER2 -Mutant Non–Small-Cell Lung Cancer
13小时前
待确认
Trastuzumab Deruxtecan in Patients With HER2-Overexpressing NSCLC: Results From Part 1 of the Open-Label, Multicenter, Phase 1b DESTINY-Lung03 Trial
13小时前
已完结
Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial
13小时前
待确认
Strategies of overcoming osimertinib resistance in EGFR-mutated non-small cell lung cancer
13小时前
已完结
Management of HER2 alterations in non-small cell lung cancer – The past, present, and future
14小时前
已完结
ERBB2 mutation landscape in non-small cell lung cancer patients in Northeast China
1天前
待确认
Comparative effectiveness research in inflammatory bowel disease: Real-world evidence for real world decisions
9天前
已完结
皖公网安备34019202002308
